Abstract
The classical endogenous noncatecholic phenylethylamines, phenylethylamine (PEA), phenylethanolamine, p-tyramine and p-octopamine appear to be involved in peripheral and central nervous system synaptic transmission mechanisms (1,2). The physiological and pharmacological actions of PEA appear of particular importance as alterations in the metabolism of this amine has been postulated to contribute to the pathophysiology of a number of neuropsychiatric disorders (3–7), migraine (8,9) and diabetes (10). In order to better understand the molecular basis of PEA actions we have examined the relationship between the chemical structure, the analgesic activity and kinetic parameters of degradation by monoamine oxidase (MAO) of a series of monosubstituted derivatives of PEA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mosnaim A. D. and Wolf M. E. (eds.) (1978) Non-catecholic Phenylethylamines, Part I:Phenylethylamine; Biological Mechanisms and Clinical Aspects. Marcel Dekker, New York.
Mosnaim A. D. and Wolf M. E. (eds.) (1980) Non-catecholic Phenylethylamines, Part 2: Phenylethanolamine, Tyramines and Octopamine. Marcel Dekker, New York.
Mosnaim A. D., Inwang E. E., Sugerman J. H., DeMartini W., and Sabelli H. C. (1973) Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat. 6, 235–257.
Sabelli H. C. and Mosnaim A. D. (1974) Phenylethylamine hypothesis of affective behavior. Am. J. Psychiat. 131, 695–699.
Sandler M. and Reynolds G. P. (1976) Does phenylethylamine cause schizophrenia? Lancet 1, 70–71.
Karoum F., Linniola M., Potter W. Z., Chuang L.-W., Goodwin F. K., and Wyatt R. J. (1982) Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients. Psychiat. Res. 6, 215–222.
Wolf M. E. and Mosnaim A. D. (1983) Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacol. 14, 385–390.
Diamond S., Dalessio D., Graham J., and Medina J. L. (eds.) (1975) Vasoactive Substances Relevant to Migraine. Charles C. Thomas, New York.
Mosnaim A. D., Wine R., Karoum F., Diamond S. and Wolf M. E. (1982) Methionine enkephalin, phenylethylamine, phenylacetic acid, platelet monoamine oxidase, and prolactin in plasma of migraine patients. Clinical Pharmac. and Therap. 31, 251–252.
Mosnaim A. D., Karoum F., Zeller A., Callaghan O. H., Singh S. P., and Wolf M. E. (1982) Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethy1amines in insulin-dependent diabetic subjects. Clin. Chim. Acta 126, 237–242.
Zeller E. A., Mosnaim A. D., Borison R. L., and Huprikar S. V. (1976) Phenylethylamine: Studies on the mechanism of its physiological action, in Advances in Biochemical Psychopharmacology, Vol. 15: First and Second Messengers—New Vistas, pp. 75–86. Raven Press, New York.
Kochli H. and von Wartburg J. P. (1978) A sensitive photometric assay for monoamine oxidase. Anal. Biochem. 84, 127–135.
Ehrenpreis S., Balagot R. C., Comaty J. E., and Myles S. B. (1979) Advances in Pain Research and Therapy, Vol. 3, pp. 479–488. Raven Press, New York.
Ungar F., Mosnaim A, D., Ungar B., and Wolf M. E. (1978) Preliminary studies of the sodium borohydride stabilizable binding of phenylethylamine and tyramine to brain preparation. Res. Commun. Chem. Pathol. Pharmacol. 19, 427–434.
Hansen T. R., Greenberg J., and Mosnaim A. D. (1980) Direct effect of phenylethylamine upon isolated rat aortic strip. Eur. J. Pharmacol. 63, 95–101.
Mosnaim A. D., Vazquez A., and Nair V. (1982) First World Congress on Toxicology and Environmental Health, Washington, D. C. (Abst.).
Jackson D. M. and Smythe D. B. (1973) The distribution of β–phenylethylamine in discrete regions of the rat brain and its effect on brain noradrenaline, dopamine and 5-hydroxytryptamine levels. Neuropharmacology 12, 663–668.
Sabelli H. C., Vazquez A. J., Mosnaim A. D., and Madrid-Pedemonte L. (1974) 2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation. Nature 248, 144–145.
Borison R. L., Havdala H. S., and Diamond B. I. (1977) Chronic phenylethylamine-induced stereotypy in rats: A new animal model for schizophrenia? Life Sci. 21, 117–122.
Dourish C. T. (1982) A pharmacological analysis of the hyperactivity syndrome induced by 3-phenylethylamine in the mouse. Br. J. Pharmac. 77, 129–139.
Sloviter R. S., Connor J. D., and Drust E. G. (1980) Serotonergic properties of 3-phenylethylamine in rats. Neuropharmacology 19, 1071–1074.
Goudie A. J. and Buckland C. (1982) Serotonin receptor blockade potentiates the behavioral effects of β-phenylethylamine. Neuropharmacology 21, 1267–1272.
Garzon J., Moratalla R., and Del Rio J. (1980) Potentiation of the analgesia induced in rats by morphine or [D-Ala2]-Metenkephalinamide after inhibition of brain type B monoamine oxidase: The role of phenylethylamine. Neuropharmacology 19, 723–729.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 The Humana Press Inc.
About this chapter
Cite this chapter
Mosnaim, A.D., Wolf, M.E., Zeller, E.A. (1984). Degradation Kinetics by MAO of PEA Derivatives. A Model for the Molecular Basis of their Analgesic and Behavioral Effects?. In: Boulton, A.A., Baker, G.B., Dewhurst, W.G., Sandler, M. (eds) Neurobiology of the Trace Amines. Humana Press. https://doi.org/10.1007/978-1-4612-5312-9_25
Download citation
DOI: https://doi.org/10.1007/978-1-4612-5312-9_25
Publisher Name: Humana Press
Print ISBN: 978-1-4612-9781-9
Online ISBN: 978-1-4612-5312-9
eBook Packages: Springer Book Archive